NIH Archive — Page 39 of 93

Futuristic blue digital illustration combining a DNA double helix with circuit-board patterns, glowing numbers, and streams of binary code.
July 26, 2018

Vanderbilt study links gene expression, disease association data

An international team of researchers has integrated gene expression and disease association data to better understand the biological mechanisms of complex human diseases.

Portrait of Beth Malow, MD, MS, smiling and wearing a red jacket and pearl necklace.
July 26, 2018

VUMC’s membership in NIH NeuroNEXT network renewed

The National Institutes of Health (NIH) has renewed Vanderbilt University Medical Center’s membership in NeuroNEXT, a research network that helps streamline Phase 2 clinical trials for brain disorders.

Stylized medical illustration of intertwined intestinal loops glowing orange and red against a dark blue abdominal silhouette, with scattered dark circular markings on the intestines.
July 19, 2018

Novel insights on “leaky” gut

A protein involved in binding cells together helps maintain the integrity of the intestinal mucosa and plays a protective role in ulcerative colitis.

Stylized green molecular model beside blue DNA double-helix structures.
July 19, 2018

New player in DNA damage repair

New findings open opportunities to understand mechanisms of DNA repair for a toxic form of DNA damage.

Colorful molecular structure diagram showing several intertwined protein-like chains above and below a horizontal red line.
July 19, 2018

Fueling the MATE transporter

Vanderbilt researchers used spectroscopy to understand how a drug transporter pumps drugs out of cells, findings that are important for developing novel anti-cancer and anti-bacterial drugs that can overcome drug resistance.

Two researchers in white lab coats stand in a biomedical laboratory surrounded by equipment and workstations.
July 19, 2018

Team finds potent antibodies against three Ebola viruses

Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.